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Abstract
Background: Activation of muscarinic M1 receptors is mediated via interaction of orthosteric
agonists with the acetylcholine binding site or via interaction of allosteric agonists with different
site(s) on the receptor. The focus of the present study was to determine if M1 receptors activated
by allosteric agonists undergo the same regulatory fate as M1 receptors activated by orthosteric
agonists.
Results: The orthosteric agonists carbachol, oxotremorine-M and pilocarpine were compared to
the allosteric agonists AC-42, AC-260584, N-desmethylclozapine and xanomeline.  All ligands
activated M1 receptors and stimulated interaction of the receptors with β-arrestin-1. All ligands
reduced cell surface binding and induced the loss of total receptor binding. Receptor internalization
was blocked by treatment with hypertonic sucrose indicating that all ligands induced formation of
clathrin coated vesicles. However, internalized receptors recycled to the cell surface following
removal of orthosteric, but not allosteric agonists. Whereas all ligands induced loss of cell surface
receptor binding, no intracellular vesicles could be observed after treatment with AC-260584 or
xanomeline. Brief stimulation of M1  receptors with AC-260584 or xanomeline resulted in
persistent activation of M1 receptors, suggesting that continual receptor signaling might impede or
delay receptor endocytosis into intracellular vesicles.
Conclusion: These results indicate that allosteric agonists differ from orthosteric ligands and
among each other in their ability to induce different regulatory pathways. Thus, signaling and
regulatory pathways induced by different allosteric ligands are ligand specific.
Background
Muscarinic M1 receptors are the predominant muscarinic
receptor subtype expressed in the brain with high levels of
expression in the cerebral cortex and hippocampus. Mus-
carinic M1 receptors are believed to mediate many impor-
tant central processes such as cognition and memory [1,2]
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and thus are targeted for the development of drugs to treat
various neurological disorders, such as Alzheimer's dis-
ease. However, discovery of selective M1 agonists has been
challenging due to the highly conserved orthosteric acetyl-
choline binding site of muscarinic receptors. Recent struc-
ture-function studies have led to the identification of
functionally selective muscarinic M1 agonists [3-8]. Muta-
genesis studies have shown that mutations that abolish
activation of M1 receptors by orthosteric ligands do not
affect, and in some cases even enhance, activation by these
selective ligands [4,9]. These novel selective ligands have
been named allosteric M1 agonists because their mode of
interaction with M1  receptor is different from that of
orthosteric agonists [4,10-12].
While allosteric M1 agonists appear to bind to a receptor
domain different from that of the orthosteric ligands, in
many cases they have been shown to induce similar sign-
aling pathways as the orthosteric M1 agonists. Moreover,
allosteric M1 agonists can displace conventional orthos-
teric M1 muscarinic radioligands such as [3H]-NMS [4,12-
14]. Based on these data, it has been suggested that there
is some degree of overlap between the allosteric and
orthosteric binding sites on the M1 receptor for these lig-
ands [12].
A recent study [14] has demonstrated that some allosteric
muscarinic M1 agonists differentially activate downstream
signaling pathways for M1receptors, suggesting "stimulus
trafficking" with respect to receptor signaling events.
However, presently little is known about the potential dif-
ferences between orthosteric and allosteric muscarinic M1
ligands in modulating receptor regulatory pathways such
as internalization, down-regulation or recycling. The
present study was carried out to assess these cellular regu-
latory events in muscarinic M1 receptors in response to a
number of allosteric and orthosteric M1 agonists.
In order to understand the mode of interaction of a ligand
with the receptor, it is important to characterize receptor-
ligand interaction in multiple assays and in multiple sys-
tems [12] and also to correlate it with the induction of
downstream signaling and regulatory pathways. Receptor
regulatory events include receptor processes such as
desensitization (rapid uncoupling of receptors from sign-
aling molecules), internalization/endocytosis (transloca-
tion of receptors from the cell surface into intracellular
vesicles) and down-regulation (translocation of receptors
into lysosomes where receptors are degraded).
In the present study, several different assays were
employed in order to comprehensively evaluate various
intracellular signaling and regulatory processes. The
results demonstrate that allosteric ligands differ from
orthosteric ligands and amongst each other in induction
of internalization, down-regulation, recycling and signal-
ing of M1 muscarinic receptors.
A preliminary report of the present work was presented at
the meetings for Society for Neuroscience, 2007 and at
Recent Advances in Muscarinic Receptor Pharmacology
and Therapeutics Colloquium, 2008.
Results
Allosteric and orthosteric agonists induce signaling of 
human muscarinic M1 receptors
Receptor activation in response to agonist treatment was
measured by two different assays, Receptor Selection and
Amplification assay (RSAT) and phosphatidylinositol (PI)
hydrolysis assay (Table 1). These two assays showed sim-
ilar results for all compounds tested. Among the ligands
tested, AC-42 and NDMC were shown to be partial ago-
nists in both assays, while all the other compounds were
able to activate M1 receptor with full efficacy as compared
to carbachol.
Allosteric M1 agonists, AC-260584 and xanomeline, show 
distinctive effects on receptor endocytosis
Treatment with all the orthosteric and allosteric M1 ago-
nists resulted in reduced cell surface binding (Figure 1A)
as measured with [3H]-NMS, while having no effect on
total receptor binding as measured with [3H]-QNB (Figure
1B).
To visualize endocytosis of M1 receptors from the cell sur-
face into endosomes, translocation of the M1 receptors
was followed using confocal microscopy. The results dem-
onstrated that treatment with carbachol, pilocarpine,
oxotremorine-M, NDMC and AC-42 induced transloca-
tion of cell surface receptors into intracellular vesicles,
while no receptors could be visualized in the endosomes
after treatment with AC-260584 or xanomeline (Figure 2).
Table 1: Activation of muscarinic M1 receptors as measured by 
R-SAT® and PI assays
M1 Agonist RSAT PI Hydrolysis
pEC50 % Efficacy pEC50 % Efficacy
Carbachol 6.2 ± 0.3 100 ± 10 6 ± 0.1 100 ± 3
Oxotremorine-M 7.4 ± 0.3 105 ± 13 7.0 ± 0.1 106 ± 7
Pilocarpine 5.7 ± 0.2 93 ± 15 6.2 ± 0.9 97 ± 31
Xanomeline 7.4 ± 0.5 120 ± 21 8.4 ± 0.2 99 ± 12
NDMC 7.4 ± 0.2 76 ± 13 7.1 ± 0.4 67 ± 23
AC-42 6.7 ± 0.3 62 ± 14 6.5 ± 0.5 79 ± 14
AC-260584 7.6 ± 0.4 102 ± 21 7.7 ± 0.3 90 ± 17
Activities of compounds on human M1 receptors were compared 
using two different assay; RSAT in transiently transfected NIH-3T3 
cells and PI hydrolysis in stable CHO-M1 cells. Data for each 
compound is normalized to carbachol for both assays. Values 
presented are mean ± SD from 2-19 independent experiments 
carried out in triplicate.BMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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Translocation of M1 receptors seen with these ligands was
blocked by treatment with the muscarinic antagonist atro-
pine (Figure 2).
The time course of receptor internalization was assessed
for some of these compounds. Carbachol and NDMC
induced translocation of receptors into intracellular vesi-
cles within five minutes of treatment, while AC-260584
did not induce formation of any vesicles even after 2
hours of treatment (Figure 3).
Hypertonic sucrose treatment blocks M1 receptor 
internalization
Treatment of the HEK-293 cells with hypertonic sucrose
blocked loss of cell surface receptor binding induced by all
allosteric and orthosteric M1 agonists (Figure 4B). These
results indicate that the loss of cell surface receptors
induced by all these compounds are mediated via a com-
mon cellular pathway, namely by formation of clathrin-
coated pits.
Lack of M1 receptor recycling following treatment with 
allosteric agonists
Receptor recycling to the cell surface following removal of
the agonists was assessed in HEK-293 cells transiently
transfected with hM1. Agonist removal after treatment
with carbachol and oxotremorine-M resulted in recovery
of cell surface binding as measured by [3H]-NMS. How-
ever, no receptor recycling could be observed following
treatment with the allosteric agonists, AC-42 and AC-
260584 or after treatment with xanomeline. The extent of
recovery of [3H]-NMS binding following removal of each
ligand is summarized in Table 2.
Allosteric and orthosteric M1 agonists induce down-
regulation of M1 receptors in CHO-M1 cells
The extent of down-regulation of M1 receptors following
treatment with various ligands was measured in CHO
cells stably expressing hM1 receptors. Treatment of the
cells with all the orthosteric and allosteric ligands for 24
hours resulted in a loss of total receptor binding (Figure
5A). Treatment with similar concentrations of the agonists
for 2 hours did not result in any loss of [3H]-QNB bind-
ing, confirming proper removal of ligands from the cells
(Figure 5B). Receptor down-regulation induced by each of
these ligands was mediated by interaction with the M1
receptors, as it could be blocked by treatment with the
muscarinic antagonists atropine (1 μM) (Figure 5A), sco-
polamine (1 μM) or pirenzepine (10 μM) (data not
shown).
Allosteric and orthosteric M1 agonists induce recruitment 
of  -arrestin-1 to M1 receptors
The ability of different muscarinic agonists to induce asso-
ciation of the M1 receptors with β-arrestin-1 in real time
Loss of binding to cell-surface receptors following treatment  with orthosteric and allosteric ligands Figure 1
Loss of binding to cell-surface receptors following 
treatment with orthosteric and allosteric ligands. 
Binding was measured in transiently-transfected HEK-293 
cells. (A) Cell surface receptor binding was assessed with the 
[3H]-NMS and (B) total receptor binding was assessed with 
[3H]-QNB as detailed in Methods. Surface binding was nor-
malized to total receptor binding and expressed as % of con-
trol (no drug). Average receptor expression in untreated 
transiently transfected HEK cells was 325,000 sites/cell as 
measured by [3H]-NMS and 360,000 site/cell as measured by 
[3H]-QNB. Figure shows the mean results (± S.D.) from test 
compounds assayed in triplicate in a representative experi-
ment repeated 2-6 times. Cell surface receptors remaining 
after treatment with each compound were as listed; No 
drug, 102% ± 13, carbachol, 45% ± 10, oxotremorine-M, 46% 
± 8, pilocarpine, 65% ± 12, xanomeline, 69% ± 5, NDMC, 
52% ± 10, AC-42, 60% ± 14, AC-260584, 55% ± 11. Statisti-
cally significant difference compared to no drug, * = p < 
0.001, ** = p < 0.05 (Student t-test, Graph-Pad, Prism).BMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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was quantified using the BRET-2 assay. Most ligands were
able to induce an association of the receptor with β-arres-
tin-1, albeit with different potencies and efficacies (Table
3). Relative efficacies of the compounds were determined
as compared to carbachol. Oxotremorine-M was a full
agonist in this assay, while pilocarpine, xanomeline, AC-
260584, and AC-42, were partial agonists with relative
efficacies in the range of 12-26%. NDMC did not show
any agonist activity at M1 as measured by BRET-2.
M1 receptor endocytosis is distinctively affected by AC-
260977 an AC-260584 related ligand
To determine whether the lack of induction of receptor
endocytosis observed with AC-260584 was unique to this
compound or to other compounds with similar structure,
the effects of three closely related compounds with vari-
ous activities (Table 4) on receptor internalization were
assessed. While two of these compounds induced translo-
cation of the receptors from cell surface into intracellular
vesicles in HEK-293 cells, one compound, AC-260977,
did not (Figure 6). This data indicates that even com-
pounds with close structural similarity to AC-260584 can
behave differently with respect to inducing receptor endo-
cytosis.
AC-260584 and xanomeline induce persistent activation of 
M1 receptors
To investigate other ligand-mediated receptor modifica-
tions, changes in receptor coupling were assessed in CHO-
M1 cells treated with various ligands. Cells were briefly
exposed to each agonist and PI accumulation was meas-
ured following removal of the agonist. Basal levels of PI
hydrolysis were elevated after only one minute of expo-
sure to AC-260584 and xanomeline. Elevation of basal
receptor activity was not seen following treatment with
carbachol, NDMC or AC-42 (Figure 7). These data suggest
that only one minute of treatment with AC-260584 and
xanomeline can induce a modification in the receptor
conformation resulting in continuous signaling of the
receptor in the absence of continued presence of the ago-
nist. This increased basal activity of the receptors follow-
ing treatment with AC-260584 and xanomeline was
Localization of M1 receptors after treatment with various lig- ands as visualized by confocal microscopy Figure 2
Localization of M1 receptors after treatment with 
various ligands as visualized by confocal microscopy. 
Cells were treated with various compounds (1 mM carba-
chol, 1 μM oxotremorine-M, 10 μM pilocarpine, 1 μM 
xanomeline, 10 μM NDMC, 10 μM AC-42 or 10 μM AC-
260584) for 2 hrs at 37°C in the absence or presence of 100 
nM atropine. The agonist concentrations used were chosen 
to ensure maximum activation of endocytic pathway. These 
concentrations were higher than those used in binding 
assays. However the possibility of residual ligand confounding 
the results was not a concern since the site of interaction 
with the monoclonal antibody (N-terminal tail of the recep-
tor) is distinct from the agonist binding sites. Images are from 
a representative experiment repeated 3 times with similar 
results.
Time course of receptor internalization as visualized by con- focal microscopy Figure 3
Time course of receptor internalization as visualized 
by confocal microscopy. Translocation of cell surface 
receptors into intracellular vesicles was measured for carba-
chol (1 mM), NDMC (10 μM) and AC-260584 (10 μM). 
Images are from a representative experiment repeated 2-3 
times with similar results.BMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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partially blocked in the presence of increasing concentra-
tions of the inverse agonist atropine (data not shown).
Discussion
The present study was designed to characterize various
receptor regulatory pathways initiated after treatment
with allosteric or orthosteric M1agonists. We demonstrate
that specific regulatory pathways initiated after activation
of M1 receptors with different ligands are unique to each
ligand and not due to the allosteric or orthosteric nature
of receptor-ligand interaction.
Among the M1 agonists in the present study, AC-42 and
AC-260584 have been characterized as allosteric agonists
[4,12,15]. Other compounds, NDMC and xanomeline,
were reported to have an allosteric component in their
interaction with M1  receptors [4,9,13,16]. Carbachol,
oxotremorine-M and pilocarpine are classical orthosteric
agonists.
All agonists in this study were characterized as either full
agonists or high efficacy partial agonists at M1 receptors as
measured by RSAT and PI assays. No correlation could be
made between efficacy or potency of each agonist and its
efficacy in activation of various receptor regulatory proc-
esses. Moreover, none of the agonists studied induced
receptor desensitization, as measured by the lack of a shift
in carbachol dose response curve or a change in maximal
response in PI hydrolysis assay (data not shown). Still, the
possibility of desensitization of other signaling pathways
cannot be ruled out.
To assess the differences in receptor regulatory processes
induced by each agonist, the extent of loss of cell surface
receptors and total receptors were evaluated. All ligands
were capable of inducing a loss of receptor binding. These
results indicate that the processes of receptor internaliza-
tion and down-regulation are induced after treatment
with all these ligands.
To further assess receptor internalization/endocytosis,
confocal microscopy was used to visualize receptor local-
ization. After treatment with orthosteric ligands, carba-
chol, pilocarpine and oxotremorine-M, M1  receptors
Treatment with hypertonic sucrose blocked internalization  induced by all ligands studies Figure 4
Treatment with hypertonic sucrose blocked internal-
ization induced by all ligands studies. Cells were treated 
without (A) or with (B) 0.4 M sucrose during treatment with 
the various ligands at indicated concentrations. Receptors 
remaining at the cell surface were quantitated. Graphs are 
mean results (± S.D.) from test compounds run in triplicate 
in a representative experiment repeated 2 times with similar 
results.
Table 2: Recycling of muscarinic receptors after treatment with 
various ligands
No recycle 3 h recycle
No drug 100 100
Carbachol 48 ± 4* 102 ± 10
Oxotremorine-M 60 ± 2* 97 ± 1
Xanomeline 65 ± 5* 69 ± 7*
AC-42 63 ± 3* 69 ± 1*
AC-260584 59 ± 2* 64 ± 3*
HEK-293 cells expressing hM1 were treated with various ligands for 
30 minutes as indicated in the table. Concentrations of ligands used 
were as follows; carbachol, 100 μM; oxotremorine-M, 1 μM; 
xanomeline, 100 μM; AC-42, 10 μM; and AC-260584, 1 μM and 
similar to concentration used in the internalization assays. Values 
presented are % receptors on the cells surface. Data presented is the 
average from 2 independent experiments carried out in triplicate. 
Statistically significant difference compared to no drug, * = p < 0.05, 
(Student t-test, GraphPad, Prism).
No recycling could be observed after treatment with NDMC (1 μM), 
71% cell surface receptor after 3 hours of recycling (n = 1).BMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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could be visualized in endosomes. However, after treat-
ment of the cells with the allosteric agonist AC-260584,
no receptors could be observed in the endosomes. To test
the hypothesis that allosteric interaction with the recep-
tors was responsible for this difference, we tested several
other allosteric agonists for their propensity to induce
receptor endocytosis into endosomes. The allosteric lig-
ands AC-42 and NDMC were able to induce receptor
internalization/endocytosis, while xanomeline was not.
To determine whether lack of endocytosis was associated
with the specific structure of AC-260584, three close ana-
logues of this compound were studied. Two of these com-
pounds induced internalization/endocytosis of M1
receptor while one did not. These results indicate that
allosteric nature of the ligand-receptor interaction is not
sufficient explanation for lack of ligand-induced endocy-
tosis.
It was puzzling that no intracellular vesicles could be seen
after treatment with AC-260584 and xanomeline while
binding to cell surface receptors was reduced after treat-
ment with these ligands. One possible reason for this
observation could be induction of different endocytic
pathways by these ligands. It has been previously demon-
strated that carbachol-induced internalization of M1
receptors is mediated via clathrin-coated pits [17]. Forma-
tion of clathrin-coated vesicles can be blocked by treat-
ment with hypertonic sucrose solution [18-21]. In order
to investigate whether AC-260584 and xanomeline
induce similar endocytic pathways as carbachol, cells were
pretreated with hypertonic sucrose solution to block for-
mation of clathrin coated vesicles. Hypertonic sucrose
treatment blocked receptor internalization induced by all
the agonists, indicating that formation of clathrin coated
vesicles is necessary for the loss of cell surface receptor
Down-regulation of Muscarinic M1 Receptors in CHO Cells Figure 5
Down-regulation of Muscarinic M1 Receptors in CHO Cells. (A) Total receptor binding remaining following 24 hours of 
treatment with various agonists, in the presence or absence of the muscarinic antagonist atropine, was measured in CHO cells 
stably expressing hM1 receptors. The data presented are mean ± S.D from 3-6 pooled experiments performed in triplicate. 
Total binding is expressed as % of control at 24 hours. Total receptor binding remaining after treatment with each ligand was; 
No drug, 100% ± 3, carbachol, 49% ± 3, xanomeline, 48% ± 12, NDMC, 49% ± 6, AC-42, 56% ± 7, AC-260584, 56% ± 4. Sta-
tistically significant difference compared to no drug, * = p < 0.001, (Student t-test, GraphPad, Prism). (B) No loss in [3H]-QNB 
binding could be measured when the cells were treated with the same concentration of each ligand for only 2 hours, confirm-
ing proper removal of ligands during washing.
Table 3: Activation of muscarinic M1 receptors as measured by 
BRET-2
BRET-2
Compound pEC50 %Efficacy
Carbachol 4.6 ± 0 100 ± 0
Oxotremorine-M 5.6 ± 0.2 100 ± 12
Pilocarpine 5.4 ± 0.3 16 ± 3*
NDMC NA
AC-42 5.4 ± 0.6 12 ± 0.7*
AC-260584 6.2 ± 0.14 26 ± 6*
Xanomeline 7.2 ± 0.3 16 ± 6*
M1 BRET-2 assays were performed to determine potency and efficacy 
of agonists to stimulate β-arrestin-1 recruitment. Data presented are 
mean ± S.D. from 2-3 independent experiments carried out in 
triplicate. Statistically significant difference compared to no drug, * = p 
< 0.001, (Student t-test, GraphPad, Prism). Based on student t-test, 
efficacies for AC-42, AC-260584, xanomeline and pilocarpine were 
not statistically different, p > 0.5. NA: No measurable agonist activity.BMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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binding after treatment with all these ligands. This obser-
vation suggests that divergence of receptor regulatory
processes induced by the different ligands occur down-
stream from the formation of clathrin-coated pits.
Internalization of G-protein coupled receptors has been
shown to involve interaction with β-arrestin [22-27].
Moreover, it has been suggested that endocytosis and sig-
naling of muscarinic M1 receptors involve interaction with
β-arrestin [23,24,26]. In order to determine if absence of
interaction with β-arrestin attributed towards the differ-
ences observed in vesicle formation, interaction of M1
receptors with β-arrestin-1 was assessed using BRET-2
assays. All ligands studied were able to stimulate recruit-
ment of β-arrestin-1 to M1 receptors. While carbachol and
oxotremorine-M were full agonists in BRET-2 assay, all
other ligands, including pilocarpine, were partial agonists.
Other studies have also described pilocarpine as a partial
agonist at M1 receptors [28,29]. Although AC-260584 and
xanomeline stimulated an increase in the BRET-2 signal
with lower efficacy compared to carbachol and oxotremo-
rine-M, the lower efficacy in this interaction could not
explain the absence of vesicle formation in response to
these ligands. This conclusion is based on the fact that
while both AC-42 and pilocarpine have similar potency
and efficacy in the BRET-2 assay compared to AC-260584
and xanomeline, both compounds can induce receptor
endocytosis into endosomes.
Another difference observed between the receptor regula-
tory processes induced by the different agonists was the
difference seen in the recycling of the receptors back to the
cell surface. While M1 receptors recycled back to the cell
Internalization of muscarinic M1 receptors by analogues of  AC-260584 Figure 6
Internalization of muscarinic M1 receptors by ana-
logues of AC-260584. HEK-293 cells expressing EE-hM1 
were treated with 1 μM of each ligand and localization of EE-
hM1 receptors were visualized using confocal microscopy. 
Images are from a representative experiment repeated 2-3 
times with similar results.
Table 4: Activation of muscarinic M1 receptors by analogues of 
AC-260584 as measured by R-SAT
M1 Agonist RSAT
pEC50 %Efficacy
AC-260515 6.6 ± 0.2 66 ± 16
AC-262469 7.2 ± 0 107 ± 16
AC-260977 7.7 ± 0.1 107 ± 10
Activities of AC-260584 analogues on human M1 receptors were 
assessed using R-SAT in transiently transfected NIH-3T3 cells. Data 
presented are mean ± SD from 5-7 independent experiments carried 
out in triplicate.
Continued activation of M1 receptors after agonist treatment Figure 7
Continued activation of M1 receptors after agonist 
treatment. CHO-hM1 cells were treated with agonists for 1 
minute prior to washing and incubation in the presence of 10 
mM LiCl2. Total IP accumulation after 1 hour was measured 
as described under Methods. Data presented are mean ± SD 
for duplicate measurements from a representative experi-
ment repeated twice with similar results. Statistically signifi-
cant difference compared to no drug, * = p < 0.05, (Student 
t-test, GraphPad, Prism).BMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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surface after treatment with orthosteric ligands (carbachol
and oxotremorine-M) following treatment with allosteric
ligands (AC-260584, AC-42, xanomeline or NDMC) and
ligand removal, binding to cell surface receptors remained
low. These results suggest that after removal from the cell
surface, receptors sequestered following treatment with
the latter set of compounds do not return to the cell sur-
face. We have shown that after a brief treatment with some
of these ligands, M1 receptors remain active and produce
higher basal levels of inositol phosphates. Thus, it is likely
that receptors treated with these ligands remain in a
sequestered state and continue to signal via G-proteins
(AC-260584 and xanomeline) or other signaling proteins.
Following this continued signaling event, the receptors
are then processed through various degradative processes
and subsequently destroyed.
Based on the classical paradigm for GPCR regulation,
receptor activation by agonist leads to rapid phosphoryla-
tion, interaction with β-arrestin and sequestration into
clathrin-coated pits. Coated pits containing the receptors
pinch off the plasma membrane into intracellular vesicles
via a dynamin mediated process. Internalized receptors
are then de-phosphorylated and recycled back to the cell
surface for further stimulation (Figure 8A) or are routed to
the lysosomes for degradation, a process known as down-
regulation [27]. Our results indicate that activation of M1
receptors by allosteric ligands do not stimulate the recy-
cling pathway in HEK-293 cells. Absence of receptor recy-
cling by these ligands implies that M1 receptors stimulated
by these agonists remain sequestered and continue to sig-
nal or are routed to the lysosomes for degradation (Figure
8B). In addition to its role in receptor regulation, receptor
endocytosis has been implicated in signaling of GPCRs
[30,31]. Signaling pattern of M1 receptors following treat-
ment of the cells with various agonists was assessed. Inter-
action of M1 receptors with caveolin after treatment with
various ligands was evaluated using confocal microscopy.
As seen previously for carbachol [17], no co-localization
of M1 receptors with caveolin was observed after treatment
with any of the allosteric agonists studied (data not
shown). The possibility of receptors continuing to signal
after treatment with some ligands and not others was
assessed by measuring inositol phosphates following only
1 minute of treatment with the ligands. While no changes
in basal levels of PI hydrolysis could be observed after
treatment with carbachol and oxotremorine-M, treatment
with AC-260584 and xanomeline resulted in increased
basal levels of inositol phosphates. These results suggest
that treatment with these compounds could render a con-
formational change in the receptor that may possibly lead
to continued signaling of M1 receptors.
Based on the results of these studies, it may be more
appropriate to classify the agonists studied (Figure 9) on
the basis of their activation of various cellular processes
rather than by the mode of interaction with various
domains of the receptor. Thus, we can classify these lig-
ands as follows; (1) carbachol and oxotremorine-M fully
activate all processes investigated. (2) Pilocarpine can
fully activate all processes except it is a partial agonist in
BRET-2 assay. (3) NDMC and AC-42 are partial agonists
of various signaling pathways of M1 receptors; fully acti-
vate internalization and down-regulation of the receptors,
but not receptor recycling processes. (4) AC-260584 and
xanomeline are full agonists at M1 as assessed by RSAT
and PI, but are partial agonists in BRET-2 assay. Both these
compounds induce loss of cell surface and total receptors,
but no recycling or vesicle formation can be measured
after treatment with these compounds. Moreover, treat-
ment with these compounds can possibly induce contin-
ued signaling of M1 receptors. These last two compounds
have the most diverse mode of interaction with M1 recep-
tors compared to all other agonist studied.
Conclusion
The results from the present study indicate that M1 signal-
ing and regulatory pathways induced by different allos-
teric M1 agonists are ligand specific. Allosteric agonists
differ from orthosteric agonists and amongst each other in
their ability to induce different regulatory processes for M1
receptors. Moreover, it is important to note that although
there are differences in how multiple types of agonists can
regulate the activity of M1 receptors, activation with allos-
teric ligands, like activation with orthosteric ligands, ulti-
mately results in receptor internalization/down-
regulation. Thus, it is expected that the normal physiolog-
ical limits on receptor signaling will occur regardless of
which agonist is used.
Methods
Materials
Human embryonic kidney (HEK-293) cells were pur-
chased from American Tissue Culture Collection. Chinese
hamster ovary (CHO) cells stably expressing human mus-
carinic M1  receptors (CHO-M1) were established as
described previously [32]. [3H]-NMS and [3H]-QNB were
purchased from GE Healthcare (Piscataway, NJ). Carba-
chol, atropine, oxotremorine-M, pilocarpine and poly-D-
lysine were purchased from Sigma-Aldrich (St. Louis,
MO). Xanomeline, N-desmethylclozapine (NDMC), AC-
260584 (4-[3-(4-butylpiperidin-1-yl)propyl]-7-fluoro-
2H-benzo[b][1,4]oxazin-3-one)), AC-42 (4-(4-butyl-
piperdin-1-yl)-1-(2-methylphenyl)butan-1-one), AC-
260515 (4-[3-(4-butyl-piperidin-1-yl)-propyl]-7-chloro-
2H-benzo[b][1,4]oxazin-3-one), AC-262469 (4-[3-(4-
cyclopropylmethyloxypiperidin-1-yl)propyl]-7-fluoro-
2H-benzo[b][1,4]oxazin-3-one) and AC-260977 ((R)-4-
[3-(4-butylpiperidin-1-yl)propyl]-7-fluoro-2H-
benzo[b][1,4]oxazin-3-one) were synthesized at ACADIABMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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Various receptor signaling and regulatory pathways Figure 8
Various receptor signaling and regulatory pathways. (A) Receptor activation by agonist leads to rapid phosphorylation, 
interaction with β-arrestin and sequestration into clathrin-coated pits. Coated pits containing the receptors pinch off the 
plasma membrane into intracellular vesicles. Internalized receptors are then de-phosphorylated and recycled back to the cell 
surface for further stimulation or are routed to the lysosomes for degradation (down-regulation). (B) Following treatment with 
some agonists it is possible that receptors do not recycle back to the surface, implying that these receptors remain seques-
tered and continue to signal before being routed to the lysosomes for degradation.BMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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Pharmaceuticals LLC. The EE-hM1 antibody was prepared
as described previously [33]. All other reagents were
obtained from common vendors.
Receptor binding assays
Two different systems were employed to assess receptor
internalization and down-regulation in response to vari-
ous ligands. This selection was based on previous data
identifying each system as the best choice for the specific
study.
Previous studies have shown that transiently transfected
HEK-293 cells efficiently internalize M1 muscarinic recep-
tors [34,35] while CHO cells do not [21]. To quantify
receptor internalization, agonist-induced decreases in cell
surface receptor binding were measured in HEK-293 cells
transiently transfected with hM1 receptor by using non
cell-permeating quaternary amine, [3H]-NMS. In addi-
tion, in each case total receptor binding was measured by
the membrane permeating tertiary amine, [3H]-QNB. In
each case, the highest concentration of agonist that did
not result in a reduction of total receptor binding after 2
hours, as measured by [3H]-QNB, was selected for the
assay. Using this process for the selection of agonist con-
centration ensured that all residual ligand had been com-
pletely removed and could not contribute to reduction of
receptor binding.
Previous studies have demonstrated that after chronic
treatment with the muscarinic agonist carbachol, hM1
receptors stably expressed in HEK-293 cells do not effi-
ciently go through receptor down-regulation process [34]
while CHO cells are a good model to study this regulatory
pathway [21,36]. Thus, in order to assess receptor down-
regulation, loss of total receptor binding was measured in
stably transfected CHO cells using [3H]-QNB. CHO-M1
cells were grown in F-12 medium supplemented with
10% fetal bovine serum.
HEK-293 cells were grown in DMEM medium supple-
mented with 10% fetal bovine serum. For studies using
transiently transfected cells, exponentially growing HEK-
Structures of various compounds Figure 9
Structures of various compounds. Structures of the orthosteric and allosteric muscarinic agonists characterized in the 
present study are represented.BMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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293 cells (6 × 106 cells) were seeded onto 10 cm tissue cul-
ture dish and transfected with hM1 in PSI vector using
FuGene HD transfection reagent (Roche Applied Sciences,
Indianapolis, IN) following manufacturer's instructions.
One day after transfection, the cells were harvested using
phosphate buffered saline (PBS) containing EDTA and
seeded onto 24-well tissue culture plates as described
below.
For receptor binding studies, cells were seeded onto 24-
well tissue culture plates (poly D-lysine coated for HEK-
293 cells), allowed to attach overnight, and then treated
with various concentrations of the compounds in serum-
free medium at 37°C for 2 hrs (internalization studies,
HEK-M1) or 24 hrs (down-regulation studies, CHO-M1).
Cells were placed on ice, washed three times with ice-cold
PBS, and incubated with PBS containing saturating con-
centration of [3H]-NMS (2 nM, internalization assay) or
[3H]-QNB (1 nM, down-regulation assays) at 12°C for 90
min [21,34]. These conditions were established previ-
ously and were sufficient for achieving equilibrium bind-
ing [21,34]. Binding assays were carried out at 12°C to
ensure no receptor recycling occurred. Cells were placed
on ice, scraped, harvested by filtration (24-well GF/B
plates, Perkin Elmer, Waltham, Massachusetts), and
washed three times with ice-cold PBS. The radioactivity on
the filters was quantitated by liquid scintillation counting
using Top Count (Perkin Elmer, Waltham, Massachu-
setts). Average hM1 receptor expression in untreated tran-
siently transfected HEK cells was 325,000 sites/cell as
measured by [3H]-NMS and 360,000 site/cell as measured
by [3H]-QNB. Average receptor expression in untreated
CHO-M1 cells was 280,000 sites/cells as measured by
[3H]-QNB. Thus receptor expression levels were roughly
similar in both these cells lines.
Recycling experiments
HEK-293 cells transiently transfected with hM1 receptors
were treated with various ligands for 30 minutes at 37°C.
Following treatment with the ligands, control (non-recy-
cle) plates were washed with ice-cold PBS and 2 nM [3H]-
NMS in PBS was added for 90 min at 12°C. Recycling
plates were washed 3× with room temperature PBS. Serum
free media was added and cells were incubated for 3 hrs at
37°C. After this incubation period, presence of receptors
at the cell surface, as measured by binding to the mem-
brane impermeable tracer [3H]-NMS, was determined as
described above.
Hypertonic sucrose treatment
HEK-293 cells transfected with hM1 receptors were plated
onto poly-D-lysine coated 24-well plates on the day after
transfection. The cells were incubated for 30 minutes in
the presence or absence of hypertonic sucrose (0.4 M)
prior to addition of the ligands and an additional incuba-
tion for 30 min with the ligands. Cells were then washed
with room temperature (RT) PBS, ice cold PBS containing
2 nM [3H]-NMS was added and binding carried out for 90
min at 12°C. Cells were removed from the plates, har-
vested onto 24-well filter plates and washed with cold
PBS. Radioactivity was quantitated by scintillation count-
ing using a Top Count scintillation counter.
Immunofluorescence confocal microscopy
Construction of hM1 gene containing the EYMPME (EE)
epitope tag (EE-hM1) and generation of mouse mono-
clonal antibody to EE tag were previously described
[17,33]. Internalization of this EE-hM1 receptor has been
well characterized and it has been shown that the N-termi-
nal tag does not interfere with normal trafficking and sig-
naling of the M1receptors [17,33].
Transiently-transfected HEK-293 cells expressing EE-hM1
receptors were grown overnight on CC2 chamber slides
(Nunc Inc., Napperville, IL). Treatment with various con-
centrations of compounds was carried out at 37°C for 2
hrs. After removing the ligands, cells were fixed for 10 min
at RT with 3.7% paraformaldehyde in PBS, and permeabi-
lized in PBS containing 0.25% fish gelatin and 0.04%
saponin. Following fixation, cells were labeled with anti-
EE monoclonal antibody for 1 h, washed three times with
PBS, incubated with Alexa Fluor 488 goat anti-mouse sec-
ondary antibody (Invitrogen, Carlsbad, CA) for 30 min in
dark, followed by three washes with PBS and one with
water. Slides were mounted using Fluoromount G
[17,33]. Images were collected on a Delta Vision Optical
Sectioning microscope consisting of an Olympus IX-70
microscope (Tokyo, Japan) and a photometrics CH 350
cooled CCD camera. An Olympus oil immersion 60×
objective was used to collect the images.
Receptor selection and amplification (RSAT) assays
Receptor Selection and Amplification (RSAT) functional
assays were carried out as described previously [4,5]. Con-
centration response curves were generated using non-lin-
ear regression to fit the data to appropriate logistic
equations using GraphPad Prism Software (Graph-Pad
Software, Inc., San Diego, CA).
Phosphatidylinositol (PI) hydrolysis assays
PI hydrolysis assays were performed as described previ-
ously with some modifications [4,5]. Exponentially grow-
ing CHO cells stably expressing hM1 muscarinic receptors
(CHO-M1) were harvested, plated onto 96-well TC plates
in media containing [3H]-myo-inositol (2 μCi/ml), and
allowed to attach overnight. On the day of the assay,
supernatant was removed and the cells washed three
times. Fresh serum-free medium containing 10 mM LiCl
and varying concentrations of each ligand was added to
the cells. After 60 minutes at 37°C, supernatant wasBMC Pharmacology 2009, 9:14 http://www.biomedcentral.com/1471-2210/9/14
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removed and 20 mM formic acid was added to the cells.
Following 60 minutes at 0°C, a sample of the supernatant
was removed and counted in the scintillation counter.
Data were analyzed using non-linear regression analysis
using GraphPad Prism Software.
Bioluminescence resonance energy transfer (BRET-2) 
assay
BRET-2 assays were performed as described [37] with the
following modifications. cDNA encoding the human
muscarinic M1  receptor was cloned into the plasmid
pRLuc(h) (Perkin Elmer Life Sciences, Waltham, Massa-
chusetts) to generate a DNA vector for expression of the
fusion protein M1-Luc (M1  carboxyl-terminally tagged
with Renilla luciferase). Beta-arrestin-1 cDNA was cloned
into plasmid DNA pGFP2  (PerkinElmer Life Sciences,
Waltham, Massachusetts) to generate a DNA vector for
expression of the fusion protein GFP2-β-arrestin-1 (β-
arrestin-1 amino-terminally tagged with GFP2). HEK-
293T (2 × 106) cells were plated onto 10 cm2 tissue culture
plates and cultured for two days. Cells were transiently co-
transfected with 1 μg of the bioluminescence donor plas-
mid encoding M1-Luc and 40 μg of the fluorescence accep-
tor plasmid encoding GFP2-β-arrestin-1 using Polyfect
(QIAGEN, Valencia, CA) following manufacturer's
instructions. Two days after transfection, cells were har-
vested and re-suspended at a density of 2 × 106 - 4 × 106
cells/ml (depending on transfection efficiency) in PBS pH
7.5, containing glucose and sodium pyruvate. BRET-2 sig-
nals were calculated as the ratio between the Renilla luci-
ferase emission and the GFP2 emission corrected by the
background emissions of non-transfected cells.
Induction of persistent activation of muscarinic receptors
CHO-M1 cells were labeled with [3H]-myo-inositol over-
night as described above for PI assays. On the day of the
assay, the cells were washed three times with PBS and
treated for 1 minute with serum free media alone, or
medium containing carbachol, AC-260584, xanomeline,
AC-42 or NDMC. Basal levels of PI turnover after this 1
minute of treatment with each ligand was measured by
washing off the ligand, addition of assay buffer containing
10 mM LiCl2 and incubation for an additional 60 minutes
at 37°C [38]. Inositol phosphate levels were assessed as
described above.
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